Nasopharyngeal Carcinoma Gordon Research Conference (GRC) is organized by Gordon Research Conferences (GRC) and will be held from May 09 - 14, 2021 at Courtyard by Marriott Hong Kong Sha Tin, Sha Tin, Hong Kong, China. Description: Nasopharyngeal carcinoma (NPC) is a virus-associated epithelial malignancy arising from nasopharynx and has the highest incidence in South China and Southeast Asia. This deadly cancer is usually diagnosed at advanced stage, resulting in the poor outcome as lack of efficient treatment for the recurrent and metastatic tumors. The close association of NPC with Epstein-Barr virus (EBV) infection provides a unique opportunity for development of EBV targeted therapy, vaccination and NPC screening. Understanding how EBV and aberrations in cell signaling transform normal epithelial cells and modify tumor microenvironment, how these cells escape from immune surveillance, and their molecular signatures for early diagnosis as well as for development of novel targeted and immune therapy are expected to improve treatment and outcomes. The 2021 Gordon Research Conference on Nasopharyngeal Carcinoma aims to feature cutting edge basic, translational and clinical research in NPC and provide a unique forum for idea exchange among basic scientists, clinicians, and industry representatives, will help to expand the translation of new knowledge to patient care. Through the development of an exciting scientific program, the meeting will cultivate international collaboration among basic and clinician scientists around the world to create a joint effort for promoting NPC research. The program includes keynote sessions led by world-leading speakers, who will provide lectures highlighting major advances in viral noncoding RNAs, vaccine development, immunotherapy and tumor microenvironment. Specific sessions will be dedicated to cover the EBV targeted therapy and vaccination; novel preclinical models; translational genomics; NPC prevention and screening; tumor microenvironment; innovative approaches for imaging and clinical management as well as cell based and non-cell based immunotherapies. The meeting will also feature research by new investigators and trainees through short talks selected from submitted abstracts. We believe that the scientific environment created at the meeting will help to advance the field of NPC research and to improve the overall care and cure of NPC patients. Additional details will be posted as soon as they are available.